Boule Diagnostics publishes Annual Report for 2011, and audit report with remark
In light of the shortcomings that existed during 2011 in the parent company regarding fees and charges, Boule notes that the delays are not due to lack of liquidity but due to temporary shortcomings in the administrative procedures. The latter has been corrected so that the problem will not be repeated. The delays in payment have only incurred negligible costs for the company.
For more information, please contact:
Ernst Westman, President CEO of Boule Diagnostics AB
Phone: 0708-60 88 63, e-mail: ernst.westman@boule.se
TILL REDAKTÖRERNA
Om Boule Diagnostics AB
Boule Diagnostics AB is a fast-growing diagnostics company, developing and manufacturing systems and consumables for hematology diagnostics for the public healthcare providers worldwide. The company is primarily focused on small and medium-sized hospitals, clinics and laboratories in outpatient care as well as other diagnostics companies in both human and veterinary haematology. The group is comprised of operating subsidiaries in Sweden, the US and China. Boule Diagnostics’ share is, since 2011, traded on NASDAQ OMX Nordic. www.boule.se
Latest news
-
KALLELSE TILL ÅRSSTÄMMA I BOULE DIAGNOSTICS AB 13 Apr, 2026
-
Boule Diagnostics publicerar årsredovisningen för 2025 10 Apr, 2026
-
Boule Diagnostics bokslutskommuniké 2025 11 Feb, 2026
-
Boule Diagnostics Year-end report 2025 11 Feb, 2026
-
Boule Diagnostics – Invitation to presentation of the Q4 report 2025 6 Feb, 2026
-
Boule Diagnostics – Inbjudan till presentation av Q4 2025 6 Feb, 2026
-
Boule Diagnostics Renews and Expands a Global Supply Agreement 21 Jan, 2026
-
Boule Diagnostics förnyar och utökar ett globalt leveransavtal 21 Jan, 2026